Comparing Immediate Treatment vs Conservative Approach in Elderly Men with High-Risk Prostate Cancer

What is it about?

This study aims to investigate the benefits and harms of immediate curative treatment compared to conservative treatment in older men (aged ≥75 years) with high-risk, non-metastatic prostate cancer. The study will evaluate overall survival, health-related quality of life, prostate-specific mortality, and treatment- and cancer-related morbidity. The study design is a randomized, controlled, multicentre, phase III trial conducted in Norway, Denmark, Finland, and Sweden. The primary endpoints are overall survival and health-related quality of life, while secondary endpoints include prostate-specific survival, metastasis-free survival, and various measures of morbidity and healthcare costs.

Featured Image

Why is it important?

This research is important because it aims to address the current lack of evidence on the benefits and harms of immediate curative treatment vs. conservative treatment in older patients with high-risk, non-metastatic prostate cancer. The study will evaluate the impact of treatment on overall survival, health-related quality of life, and various aspects of patient functional status, morbidity, and healthcare costs. By providing a better understanding of the outcomes in this large and increasing patient population, the study can help guide treatment decisions and improve patient care. Key Takeaways: 1. The current case for age limits in prostate cancer treatment is based on limited level 1 evidence and general misunderstandings about the long-term efficacy of stand-alone endocrine therapy in older patients. 2. Immediate curative treatment in older patients may improve prostate-specific mortality, but the benefits may only be observed in selected patients with specific tumor characteristics. 3. The study will provide insights into the feasibility of randomized clinical trials in an older patient population and help identify older patients who may benefit from immediate curative treatment.